Rama Balaraman

1.8k total citations
12 papers, 127 citations indexed

About

Rama Balaraman is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Rama Balaraman has authored 12 papers receiving a total of 127 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 3 papers in Surgery and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Rama Balaraman's work include Cancer Immunotherapy and Biomarkers (3 papers), Advanced Breast Cancer Therapies (2 papers) and CAR-T cell therapy research (2 papers). Rama Balaraman is often cited by papers focused on Cancer Immunotherapy and Biomarkers (3 papers), Advanced Breast Cancer Therapies (2 papers) and CAR-T cell therapy research (2 papers). Rama Balaraman collaborates with scholars based in United States, France and Portugal. Rama Balaraman's co-authors include Kathleen Sullivan, Joan I. Dickinson, Bhaskar Srivastava, Michael C. Perry, Syed Mahmood Haider, Marcus Smith Noel, David Sommerhalder, Scott R. Daigle, Scott Boiko and Xinyan Zhang and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Rama Balaraman

10 papers receiving 118 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rama Balaraman United States	5	56	22	20	19	18	12	127
Sarah Knispel Germany	6	42 0.8×	9 0.4×	5 0.3×	8 0.4×	6 0.3×	10	128
Sam Sollie United Kingdom	7	39 0.7×	6 0.3×	29 1.4×	3 0.2×	15 0.8×	10	298
Alexandros-Georgios Chalamandaris Belgium	6	32 0.6×	40 1.8×	26 1.3×	14 0.7×	28 1.6×	8	427
Sarah C. Wallingford United Kingdom	9	100 1.8×	4 0.2×	10 0.5×	87 4.6×	15 0.8×	12	308
Joshua H. Gordon United States	9	17 0.3×	7 0.3×	12 0.6×	6 0.3×	5 0.3×	13	263
Antoinette Anger France	6	103 1.8×	6 0.3×	11 0.6×	58 3.1×	3 0.2×	6	303
Clare Boothroyd Australia	11	23 0.4×	6 0.3×	32 1.6×	3 0.2×	27 1.5×	18	516
Cindy Chau United States	4	17 0.3×	2 0.1×	12 0.6×	12 0.6×	16 0.9×	4	188
Rita Rossi Italy	4	47 0.8×	9 0.4×	6 0.3×		45 2.5×	9	338
Yukari Taniyama Japan	8	41 0.7×	9 0.4×	3 0.1×	3 0.2×	2 0.1×	20	139

Countries citing papers authored by Rama Balaraman

Since Specialization

Citations

This map shows the geographic impact of Rama Balaraman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rama Balaraman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rama Balaraman more than expected).

Fields of papers citing papers by Rama Balaraman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rama Balaraman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rama Balaraman. The network helps show where Rama Balaraman may publish in the future.

Co-authorship network of co-authors of Rama Balaraman

This figure shows the co-authorship network connecting the top 25 collaborators of Rama Balaraman. A scholar is included among the top collaborators of Rama Balaraman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rama Balaraman. Rama Balaraman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Cardoso, Fátima, William Jacot, Sherko Küemmel, et al.. (2025). 600- vs 400-mg First-Line Ribociclib in Hormone Receptor–Positive/ ERBB2 -Negative Advanced Breast Cancer. JAMA Oncology. 11(11). 1356–1356.

Giannatempo, Patrizia, Matthew D. Galsky, I. Durán, et al.. (2025). Phase 1/2 Duravelo-1 study: Preliminary results of nectin-4–targeting zelenectide pevedotin (BT8009) plus pembrolizumab in previously untreated, cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer.. Journal of Clinical Oncology. 43(16_suppl). 4567–4567.

Noel, Marcus Smith, Bhaskar Srivastava, Scott R. Daigle, et al.. (2024). Phase 1/2 trial of the HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab: Clinical update.. Journal of Clinical Oncology. 42(16_suppl). 3083–3083. 6 indexed citations

Sommerhalder, David, Marcus Smith Noel, Scott Boiko, et al.. (2023). 751 Monotherapy results from an ongoing phase 1a dose escalation study of NDI-101150, a highly selective oral hematopoietic progenitor kinase 1 (HPK1) inhibitor. SHILAP Revista de lepidopterología. A847–A847. 3 indexed citations

Cardoso, Fátima, William Jacot, Sherko Küemmel, et al.. (2023). Abstract PD17-12: Primary efficacy and safety results from the AMALEE trial evaluating 600 mg vs 400 mg starting doses of first-line ribociclib in patients with HR+/HER2− advanced breast cancer. Cancer Research. 83(5_Supplement). PD17–12. 6 indexed citations

He, Kai, David P. Carbone, Meredith McKean, et al.. (2023). Safety and clinical activity of target-preserving anti-CTLA-4 antibody ONC-392 as monotherapy in NSCLC patients who progressed on PD(L)1-targeted immunotherapy.. Journal of Clinical Oncology. 41(16_suppl). 9024–9024. 5 indexed citations

Patel, Jay, et al.. (2021). Cardio-oncology: Capecitabine Can Sometimes be Heatbreaking Capecitabine-Induced Takotsubo Cardiomyopathy Case Report and Literature Review. Current Problems in Cardiology. 46(8). 100854–100854. 1 indexed citations

Dickinson, Joan I., et al.. (2020). Using Nature-Inspired Virtual Reality as a Distraction to Reduce Stress and Pain Among Cancer Patients. Environment and Behavior. 52(8). 895–918. 60 indexed citations

Balaraman, Rama, et al.. (2019). A Novel Approach to the Treatment of Pembrolizumab-induced Psoriasis Exacerbation: A Case Report. Cureus. 11(10). e5824–e5824. 39 indexed citations

10.

Pant, Shubham, Alexander I. Spira, Byoung Chul Cho, et al.. (2018). Evaluation of the spectrum selective RTK inhibitor sitravatinib in clear cell renal cell carcinoma (ccRCC) refractory to anti-angiogenic therapy (AAT).. Journal of Clinical Oncology. 36(15_suppl). 4568–4568. 3 indexed citations

11.

Sharman, Jeffrey P., Kathryn S. Kolibaba, Jose Azar, et al.. (2017). Evaluating the Efficacy, Safety, and Dose Dependent Activities of Entospletinib in Patients with Chronic Lymphocytic Leukemia. Blood. 130(Suppl_1). 832–832. 1 indexed citations

12.

Haider, Syed Mahmood, et al.. (2002). Hepatotoxicity of chemotherapy. Expert Opinion on Drug Safety. 1(4). 339–353. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact